EU CHMP To Review July Rejection Of Drugs For Schizophrenia, Metastatic Breast Cancer
Executive Summary
The EMA’s CHMP is this week hearing oral evidence on two products it turned down in July – for schizophrenia and metastatic breast cancer – as well as on other drugs for multiple myeloma and multiple sclerosis.